SGN-35

Known as: anti-CD30 ADC SGN-35, antibody-drug conjugate SGN-35, ADC SGN-35 
 

Topic mentions per year

Topic mentions per year

2007-2017
0520072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate with a high selectivity against CD30⁺ cell lines and more than 300… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
The treatment of anaplastic large cell lymphoma (ALCL) has largely relied on anthracycline-based chemotherapy. Targeted lymphoma… (More)
Is this relevant?
2013
2013
Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory patients… (More)
  • figure 1
  • table I
  • table II
Is this relevant?
2012
2012
The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for the treatment of relapsed Hodgkin… (More)
  • table 1
  • figure 1
Is this relevant?
2012
2012
Monoclonal antibodies have demonstrated considerable utility in the clinical treatment of cancer, but unmodified immunoglobulins… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2011
Review
2011
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous… (More)
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE SGN-35 is an antibody-drug conjugate (ADC) containing the potent antimitotic drug, monomethylauristatin E (MMAE), linked… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2009
2009
8500 Background: A defining feature of HL and sALCL is CD30 expression on malignant cells. The ADC SGN-35 comprises an anti-CD30… (More)
Is this relevant?
2008
2008
The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the… (More)
  • figure 1
  • figure 2
Is this relevant?